Fibrinogen concentrate is indicated for acquired hypofibrinogenemia with massive bleeding and for inherited fibrinogen (factor I) deficiency (also called inherited hypofibrinogenemia or afibrinogenemia) in Austria, Brazil, Bulgaria, Czech Republic, Germany, Hungary, Iran, Kuwait, Netherlands, Portugal, Romania, Switzerland, Taiwan and Turkey. In the US and some European countries, it is currently indicated only for treatment of congenital fibrinogen deficiencies (afibrinogenemia and hypofibrinogenemia but not dysfibrinogenemia).
Several pre-clinical studies show that substitution therapy with fibrinogen concentrate may reverse a dilutional coagulopathy (e.g. as a result of hypofibrinogenemia) by replacing the missing factor and restoring fibrin production and clot formation.2 Also, retrospective clinical analyses suggest a potential hemostatic effect of substitution therapy with fibrinogen concentrate in bleeding patients generally. Fibrinogen concentrate also significantly improves whole blood clot firmness and reduces the postoperative transfusion requirements in severely bleeding patients.3 A considerable amount of retrospective data exists on the use of fibrinogen concentrate (factor I concentrate), as well as a small number of prospective studies, such as Fenger-Eriksen et al. 2009.2
If you would like to learn more about perioperative bleeding and recent advances to treatment, please visit perioperativebleeding.org.
CSL Behring Products
CSL Behring's products used in the treatment of congenital fibrinogen (factor I) deficiency include:
Not all products are available in every country. To learn what products are available in your country, visit your CSL Behring country site.
4/23/2015 4:38 PM